Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis

Frontiers in Cell and Developmental Biology

Cell and Developmental Biology

Hannah M. Neuendorf¹  Glen M. Boyle²  Jacinta L. Simmons² 

[1] Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia;School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia;Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia;School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia;School of Biomedical Sciences, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia;

关键词: melanoma;    anoikis;    therapy;    metastasis;    repurposing;    targeting;   

DOI  :  10.3389/fcell.2023.1183328

 received in 2023-03-10, accepted in 2023-04-14,  发布年份 2023

来源: Frontiers

【 摘 要 】

The acquisition of resistance to anoikis, the cell death induced by loss of adhesion to the extracellular matrix, is an absolute requirement for the survival of disseminating and circulating tumour cells (CTCs), and for the seeding of metastatic lesions. In melanoma, a range of intracellular signalling cascades have been identified as potential drivers of anoikis resistance, however a full understanding of the process is yet to be attained. Mechanisms of anoikis resistance pose an attractive target for the therapeutic treatment of disseminating and circulating melanoma cells. This review explores the range of small molecule, peptide and antibody inhibitors targeting molecules involved in anoikis resistance in melanoma, and may be repurposed to prevent metastatic melanoma prior to its initiation, potentially improving the prognosis for patients.

【 授权许可】

Unknown   
Copyright © 2023 Neuendorf, Simmons and Boyle.